Fujifilm and Takeda to jointly commercialize iPS cell-derived cardiomyocytes

Fujifilm’s owns iPS cell technology and sophisticated engineering technology c through its US subsidiary, Cellular Dynamics International, and Takeda Pharmaceutical does joint research (T – CiRA) with Kyoto University iPS cell research institute (CiRA). Both companies will jointly develop and commercialize regenerative medical products using iPS cell derived cardiomyocytes.

Fujifilm news release, February 8, 2018

Most popular posts: